3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
3
Endocrine
3
Thoracic
2
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Gynecologic
2
Gastrointestinal
2
CNS
2
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
22
Neoplasms
6
Skin Neoplasms
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Uveal Melanoma
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Lung Neoplasms
3
Keratosis, Actinic
3
Hematologic Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Basal Cell
3
Breast Neoplasms
3
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Interventions
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Thyroid Carcinoma, Anaplastic
×
Dermatologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled